A phase I-II, open-label study of RAD001 [everolimus] in combination with Gleevec [imatinib; ST 1571] in refractory/resistant gastrointestinal stromal tumors.
Phase of Trial: Phase I/II
Latest Information Update: 02 Jun 2016
At a glance
- Drugs Everolimus (Primary) ; Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 31 May 2012 Additional locations identified as reported by ClinicalTrials.gov.
- 11 Jan 2011 Primary endpoint identified as (Pharmacokinetic-parameters, Objective-clinical-response) as reported by ClinicalTrials.gov.